Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Huperzine-A

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Huperzine-A: Patents, clinical trial progress, indications

Huperzine-A is an investigational drug.

There have been 10 clinical trials for Huperzine-A. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2016.

The most common disease conditions in clinical trials are Alzheimer Disease, Schizophrenia, and Cognition Disorders. The leading clinical trial sponsors are Shanghai Mental Health Center, National Institute on Aging (NIA), and Baylor College of Medicine.

There are four US patents protecting this investigational drug and twenty-nine international patents.

Recent Clinical Trials for Huperzine-A
Effects of Hearing Rehabilitative Interventions and Huperzine A on Presbycusis(Δ,kHz, dB,MMSE, AD)Zhijun BaoN/A
Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque ImagingShanghai Mental Health CenterPhase 4
Effects of Huperzine A in Treatment of Moderate to Severe TBISpaulding Rehabilitation HospitalPhase 2

See all Huperzine-A clinical trials

Clinical Trial Summary for Huperzine-A

Top disease conditions for Huperzine-A
Top clinical trial sponsors for Huperzine-A

See all Huperzine-A clinical trials

US Patents for Huperzine-A

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Huperzine-A   Start Trial Intermediates useful for the synthesis of huperzine A Georgetown University (Washington, DC)   Start Trial
Huperzine-A   Start Trial Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs BrainCells Inc (San Diego, CA)   Start Trial
Huperzine-A   Start Trial Combinations containing a 4-acylaminopyridine derivative BrainCells Inc. (San Diego, CA)   Start Trial
Huperzine-A   Start Trial Huperzine A and its derivatives as analgesic agents   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Huperzine-A

Drugname Country Document Number Estimated Expiration Related US Patent
Huperzine-A Australia 4343501 2020-03-08   Start Trial
Huperzine-A World Intellectual Property Organization (WIPO) 0166524 2020-03-08   Start Trial
Huperzine-A Australia 2006282896 2025-08-26   Start Trial
Huperzine-A Canada 2620333 2025-08-26   Start Trial
Huperzine-A European Patent Office 1928437 2025-08-26   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.